Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-06-23FDA Approved: AMLODIPINE AND OLMESARTAN MEDOXOMIL — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for the combination drug amlodipine and olmesartan medoxomil from Ascend Laboratories, LLC.
-
FDA approval · 2023-06-23FDA Approved: AMLODIPINE BESYLATE AND OLMESARTAN MEDOXOMIL — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved a supplemental application to add a fixed-dose combination of amlodipine besylate and olmesartan medoxomil from Ajanta Pharma U…
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Five, Plus Nuts and Beans for Kidneys [NA]
Clinical trial update for a Johns Hopkins study on nutrition (five, plus nuts and beans) in chronic kidney disease and hypertension; study c…
-
FDA approval · 2023-06-16FDA Approved: BYSTOLIC — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for BYSTOLIC (nebivolol hydrochloride) submitted by Allergan, Inc.
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: Motivational Interviewing (MI) Intervention to Improve Adherence [NA]
Clinical trial on Motivational Interviewing to improve adherence in adults with type 2 diabetes and hypertension has completed with posted r…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-06-12FDA Approved: METOPROLOL SUCCINATE — Original Application (Granules Pharmaceuticals Inc.)
FDA approved the Original Application (ANDA216916) for Metoprolol succinate, a generic version manufactured by Granules Pharmaceuticals Inc.
-
FDA approval · 2023-06-09FDA Approved: TELMISARTAN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for TELMISARTAN from Aurobindo Pharma Limited, authorizing a generic telmisartan product.
-
FDA approval · 2023-06-08FDA Approved: TELMISARTAN — Supplemental Application (Micro Labs Limited)
The FDA approved a supplemental application for Telmisartan from Micro Labs Limited under an ANDA. This indicates a supplemental approval fo…
-
FDA approval · 2023-06-07FDA Approved: CANDESARTAN — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for candesartan by Macleods Pharmaceuticals Limited, enabling the marketed generic candesartan produ…
-
FDA approval · 2023-06-07FDA Approved: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Losartan potassium and hydrochlorothiazide from Macleods Pharmaceuticals Limited, authorizing a …
-
FDA label_change · 2023-06-07FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA supplemental application for Losartan Potassium by Macleods Pharmaceuticals Limited, likely involving labeling changes for the generic d…
-
FDA approval · 2023-06-02FDA Approved: OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE — Supplemental Application (Par Health USA, LLC)
The FDA approved a supplemental application for a generic fixed-dose combination of olmesartan medoxomil, amlodipine besylate, and hydrochlo…
-
FDA approval · 2023-06-02FDA Approved: EPLERENONE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' Original Application for a generic version of eplerenone (Inspra).
-
FDA approval · 2023-06-02FDA Approved: NADOLOL — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Nadolol under an Original Application from Alembic Pharmaceuticals Limited, authorizing a generic Nadolol product.
-
FDA approval · 2023-06-01FDA Approved: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE — Original Application (NorthStar RxLLC)
The FDA approved the original application for a generic fixed-dose combination of olmesartan medoxomil and hydrochlorothiazide. This enables…
-
FDA approval · 2023-05-31FDA Approved: AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM — Supplemental Application (Dr. Reddy's Laboratories Inc)
FDA supplemental approval for a generic fixed-dose combination of amlodipine besylate and atorvastatin calcium by Dr. Reddy's Laboratories I…
-
FDA approval · 2023-05-26FDA Approved: METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
The FDA approved Alembic Pharmaceuticals Limited's supplemental application for a generic Metoprolol Tartrate and Hydrochlorothiazide produc…
-
FDA approval · 2023-05-26FDA Approved: METOPROLOL SUCCINATE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for metoprolol succinate from BluePoint Laboratories, allowing continued manufacture of the gene…
-
FDA approval · 2023-05-19FDA Approved: ALISKIREN — Supplemental Application (Endo USA, Inc.)
The FDA approved a supplemental application for aliskiren (Tekturna) submitted by Endo USA, Inc.
-
FDA approval · 2023-05-17FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Sun Pharmaceutical's spironolactone and hydrochlorothiazide combination product. The submission …
-
CLINICAL_TRIALS trial_result · 2023-05-17Clinical Trial Update: Chronic Hypertension and Pregnancy (CHAP) Project [Phase 4]
Phase 4 clinical trial update on chronic hypertension and pregnancy, completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-05-17Clinical Trial Update: Technology Coaching Intervention for Black Women With Hypertension [NA]
A completed clinical trial evaluating a technology coaching intervention for Black women with uncontrolled hypertension; results posted in 2…
-
CLINICAL_TRIALS trial_result · 2023-05-17Clinical Trial Update: Young Adult Hypertension Self-Management Clinical Trial [NA]
Completed clinical trial on self-management for young adults with hypertension; results posted in 2023.
-
FDA approval · 2023-05-10FDA Approved: FUROSEMIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for furosemide submitted by Hikma Pharmaceuticals USA Inc.
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: LSFG-SKIN, Laser Speckle Flowgraphy [NA]
Clinical trial LSFG-SKIN using Laser Speckle Flowgraphy was terminated; no results posted beyond status update.